Home›Dolutegravir›Dolutegravir + Empagliflozin Linagliptin Metformin Hydrochloride

Does Dolutegravir Interact with Empagliflozin Linagliptin Metformin Hydrochloride?

Dolutegravir and Empagliflozin Linagliptin Metformin Hydrochloride have a major drug interaction according to U.S. FDA drug labeling data. OCT2/MATE inhibitor that interferes with renal elimination of metformin, increasing systemic exposure and risk of lactic acidosis. The mechanism involves inhibition of organic cationic transporter-2 (oct2) and multidrug and toxin extrusion (mate) transporters. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Major
Empagliflozin Linagliptin Metformin Hydrochloride Class
Dipeptidyl Peptidase 4 Inhibitor
Management
Close medical supervision required
Data Source
U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Dolutegravir and Empagliflozin Linagliptin Metformin Hydrochloride occurs because inhibition of organic cationic transporter-2 (oct2) and multidrug and toxin extrusion (mate) transporters. Clinically, this means oct2/mate inhibitor that interferes with renal elimination of metformin, increasing systemic exposure and risk of lactic acidosis. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.

What To Tell Your Doctor or Pharmacist

If you are taking Dolutegravir and your doctor is considering prescribing Empagliflozin Linagliptin Metformin Hydrochloride (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask how frequently you should be monitored while these are co-prescribed
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Dolutegravir+💊 Empagliflozin Linagliptin Metformin Hydrochloride(Trijardy Xr)

Severity & Interaction Details

⚠️
major
Use with caution — major interaction
Serious risk of clinically significant harm. Generally avoid; if used, monitor closely.
Severity scale
MinorContra
On record
Yes
Drug A class
—
Drug B class
Dipeptidyl Peptidase 4 Inhibitor
Source
NLP:empagliflozin, linagliptin, metformin hydrochloride

What this means in plain English

OCT2/MATE inhibitor that interferes with renal elimination of metformin, increasing systemic exposure and risk of lactic acidosis.

What the FDA label says

"Inhibition of organic cationic transporter-2 (OCT2) and multidrug and toxin extrusion (MATE) transporters"

📖 Source: NLP:empagliflozin, linagliptin, metformin hydrochloride

Share this result:XFacebookWhatsAppReddit
Add more drugs
Check Dolutegravir and Empagliflozin Linagliptin Metformin Hydrochloride against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.